Susquehanna International Group, LLP Reviva Pharmaceuticals Holdings, Inc. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2025 Nov 14, 2025	SELL	$0.27 - $0.54 $92,016 - $184,032	-340,800 Reduced 90.86%	34,300 $12,000
Q2 2025 Aug 14, 2025	SELL	$0.34 - $1.12 $1,496 - $4,928	-4,400 Reduced 1.16%	375,100 $142,000
Q1 2025 May 14, 2025	BUY	$0.95 - $2.08 $213,940 - $468,416	225,200 Added 145.95%	379,500 $360,000
Q4 2024 Feb 14, 2025	BUY	$0.92 - $2.82 $74,980 - $229,830	81,500 Added 111.95%	154,300 $266,000
Q3 2024 Nov 14, 2024	SELL	$0.64 - $1.48 $33,600 - $77,700	-52,500 Reduced 41.9%	72,800 $104,000
Q2 2024 Aug 15, 2024	SELL	$1.25 - $3.79 $97,375 - $295,241	-77,900 Reduced 38.34%	125,300 $160,000
Q1 2024 May 07, 2024	BUY	$2.76 - $5.52 $64,031 - $128,063	23,200 Added 12.89%	203,200 $768,000
Q4 2023 Feb 14, 2024	SELL	$3.56 - $6.04 $856,536 - $1.45 Million	-240,600 Reduced 57.2%	180,000 $927,000
Q3 2023 Nov 14, 2023	SELL	$3.91 - $5.9 $1.17 Million - $1.76 Million	-298,100 Reduced 41.48%	420,600 $2.05 Million
Q2 2023 Aug 11, 2023	BUY	$4.42 - $8.55 $2.82 Million - $5.45 Million	637,000 Added 779.68%	718,700 $4.21 Million
Q1 2023 May 16, 2023	SELL	$3.79 - $4.87 $235,738 - $302,914	-62,200 Reduced 43.22%	81,700 $342,000
Q4 2022 Feb 14, 2023	SELL	$1.68 - $5.99 $72,576 - $258,768	-43,200 Reduced 23.09%	143,900 $611,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $2.66 $8,470 - $160,930	-60,500 Reduced 24.43%	187,100 $297,000
Q2 2022 Aug 15, 2022	BUY	$1.03 - $2.47 $204,764 - $491,036	198,800 Added 407.38%	247,600 $272,000
Q1 2022 May 16, 2022	BUY	$1.61 - $3.01 $78,568 - $146,888	48,800 New	48,800 $120,000

9.74M

585K

31.6K

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $10.2M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.